Pyxis oncology stock prediction.

Comparatively, Pyxis Oncology has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Summary Pyxis Oncology beats Aclaris Therapeutics on 10 of the 17 factors compared between the two stocks.PYXS Stock 12 Months Forecast. Based on 4 Wall Street analysts offering 12 month price targets for Pyxis Oncology in the last 3 months. The average price target is $11.67 with a high forecast of $15.00 and a low forecast of $7.00. The average price target represents a 618.15% change from the last price of $1.63.Pyxis Oncology, Inc. (PYXS) Stock Price, Quote & News - Stock Analysis 1.55 +0.15 (10.71%) At close: Nov 24, 2023, 1:00 PM 1.43 -0.12 (-7.74%) After-hours: …Pyxis Oncology (PYXS) Stock Forecast & Price Prediction. Estimation of the future price movement of Pyxis Oncology stock, based on various factors such as ...May 12, 2023 · Pyxis Oncology Inc (PYXS) stock is up 9.87% while the S&P 500 is lower by -0.69% as of 2:04 PM on Friday, May 12. PYXS has risen $0.30 from the previous closing price of $3.04 on volume of 1,647,588 shares. Over the past year the S&P 500 has risen 4.24% while PYXS has risen 57.55%. PYXS lost -$3.65 per share in the over the last 12 months.

... shares outstanding. -$2.55. CAPs Rating. The percentage of Motley Fool CAPS user ratings that predict this company will outperform the market. Based on ...Pyxis Tankers Inc. (NASDAQ:PXS) released its earnings results on Monday, November, 20th. The transportation company reported $0.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.19 by $0.07. The transportation company had revenue of $11.10 million for the quarter.

Pyxis Oncology expects to issue 4 million of PYXS stock to fuel its purchase of Apexigen. When the deal closes, it will result in current APGN shareholders owning 10% of the combined company.

People use statistics daily for weather forecasts, predicting disease, preparing for emergencies, medical research, political campaigns, tracking sales, genetics, insurance, the stock market and quality testing.BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today reported financial results for the quarter ended March 31, 2023, and provided a corporate update. Pyxis Oncology ended the first quarter of 2023 ...141.12%. Get the latest Pyxis Oncology Inc (PYXS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …Conference Call and Webcast Details. Pyxis Oncology management will host a conference call and live webcast on Tuesday, March 29, 2022, at 8:00 a.m. ET to discuss recent corporate updates. The ...

Nov 24, 2023 · Stock Price Forecast. According to 3 stock analysts, the average 12-month stock price forecast for Pyxis Oncology stock is $12, which predicts an increase of 674.19%. The lowest target is $7.00 and the highest is $15. On average, analysts rate Pyxis Oncology stock as a strong buy.

Pyxis Oncology stock was originally listed at a price of $13.20 in Oct 8, 2021. If you had invested in Pyxis Oncology stock at $13.20, your return over the last 2 years would have been -86.82%, for an annualized return of -63.69% (not including any dividends or dividend reinvestments).

The Polestar Automotive Holding UK PLC stock price gained 1.96% on the last trading day (Tuesday, 28th Nov 2023), rising from $2.04 to $2.08. During the last trading day the stock fluctuated 5.05% from a day low at $1.98 to a day high of $2.08. The price has risen in 7 of the last 10 days and is up by 0.48% over the past 2 weeks.Find the latest SEC Filings data for Pyxis Oncology, Inc. Common Stock (PYXS) at Nasdaq.com.As of March 25, 2022, the outstanding number of shares of Common Stock of Pyxis Oncology was 32,841,747. Conference Call and Webcast Details. Pyxis Oncology management will host a conference call and live webcast on Tuesday, March 29, 2022, at 8:00 a.m. ET to discuss recent corporate updates. The live call can be accessed by dialing (833) 945 ...ZIM Integrated Shipping Services (NYSE:ZIM) pays an annual dividend of $9.35 per share and currently has a dividend yield of 134.73%. ZIM has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Read our dividend analysis for ZIM.Pyxis Oncology, Inc. (PYXS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.Pyxis Oncology (PYXS) Stock Forecast & Price Prediction. Estimation of the future price movement of Pyxis Oncology stock, based on various factors such as ...Nov 29, 2023 · See the latest Pyxis Oncology Inc stock price (PYXS:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Pyxis Oncology Inc (PYXS) stock is higher by 8.35% while the S&P 500 has fallen -0.1% as of 11:49 AM on Monday, Apr 3. PYXS is higher by $0.33 from the previous closing price of $4.01 on volume of 6,295,868 shares. Over the past year the S&P 500 is down -10.42% while PYXS is higher by 21.17%. PYXS lost -$3.65 per share the over the last 12 months.Pyxis Oncology issued approximately 4.3 million shares of common stock as a result of this transaction, and immediately post-acquisition, Pyxis Oncology is expected to have 43,872,248 shares of ...You can buy or sell Pyxis Oncology and other ETFs, options, and stocks. View the real-time PYXS price chart on Robinhood and decide if you want to buy or sell commission-free. Other fees such as trading (non-commission) fees, Gold subscription fees, wire transfer fees, and paper statement fees may apply. See Robinhood Financial’s fee schedule ...As of June 30, 2023, the outstanding number of shares of common stock of Pyxis Oncology was 39,376,941. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical-stage company focused on ...Pfizer will receive an undisclosed upfront payment from Pyxis for the license to PYX-201, an ADC that targets a novel tumor-restricted antigen in certain solid tumors, and PYX-203, a DNA damaging agent that targets a well-validated tumor antigen expressed in some blood cancers. Pyxis did not disclose the specific antigens targeted.Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next-generation therapeutics that hold the potential for mono ...

Comparatively, Pyxis Oncology has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Summary Pyxis Oncology beats Aclaris Therapeutics on 10 of the 17 factors compared between the two stocks.May 12, 2023 · Pyxis Oncology Inc (PYXS) stock is up 9.87% while the S&P 500 is lower by -0.69% as of 2:04 PM on Friday, May 12. PYXS has risen $0.30 from the previous closing price of $3.04 on volume of 1,647,588 shares. Over the past year the S&P 500 has risen 4.24% while PYXS has risen 57.55%. PYXS lost -$3.65 per share in the over the last 12 months.

Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs. First subject dosed in Phase 1 trial of PYX-106, a fully human immunotherapy antibody candidate. Second dose level initiated in Phase 1 trial of PYX-201, an antibody-drug conjugate (ADC) candidate. Preliminary data from both trials on track for late-2023/early-2024 timeframe.As of May 10, 2023, the outstanding number of shares of common stock of Pyxis Oncology was 38,245,287. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical stage company focused on ...[relinking] Home Overview Mission Vision Values An Overview of Pyxis Oncology, Inc. (PYXS)General Summary of Pyxis Oncology, Inc. Pyxis Oncology, Inc. (PYXS) is a biotechnology company that specializes in the development of innovative oncology therapies. Founded in 2018, the company has quickly made a name for itself in the …Dec 1, 2023 · Analyst Price Forecast Suggests 349.06% Upside As of November 27, 2023, the average one-year price target for Pyxis Oncology is 7.14. The forecasts range from a low of 5.05 to a high of $9.45. Pyxis Oncology Inc (PYXS) stock is up 9.87% while the S&P 500 is lower by -0.69% as of 2:04 PM on Friday, May 12. PYXS has risen $0.30 from the previous closing price of $3.04 on volume of 1,647,588 shares. Over the past year the S&P 500 has risen 4.24% while PYXS has risen 57.55%. PYXS lost -$3.65 per share in the over the last 12 months.Pyxis Oncology expects to issue 4 million of PYXS stock to fuel its purchase of Apexigen. When the deal closes, it will result in current APGN shareholders owning 10% of the combined company.Their RAIN share price targets range from $11.00 to $24.00. On average, they anticipate the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 1,431.5% from the stock's current price. View analysts price targets for RAIN or view top-rated stocks among Wall Street analysts.This results in Pyxis Oncology shareholders owning approximately 90 percent and Apexigen shareholders owning approximately 10 percent of the combined company’s common stock, assuming no exercise or settlement of the converted options, restricted stock units or warrants. Pyxis Oncology issued approximately 4.3 million shares of common stock as ...Analyst Price Forecast Suggests 349.06% Upside As of November 27, 2023, the average one-year price target for Pyxis Oncology is 7.14. The forecasts range from a low of 5.05 to a high of $9.45.

Dec 1, 2023 · The transportation company reported $0.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.19 by $0.07. The transportation company had revenue of $11.10 million for the quarter. Pyxis Tankers had a trailing twelve-month return on equity of 30.88% and a net margin of 43.32%.

As of May 10, 2023, the outstanding number of shares of common stock of Pyxis Oncology was 38,245,287. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next-generation therapeutics that hold the potential for mono and combination ...

Pyxis Oncology Inc (PYXS) stock is up 9.87% while the S&P 500 is lower by -0.69% as of 2:04 PM on Friday, May 12. PYXS has risen $0.30 from the previous closing price of $3.04 on volume of 1,647,588 shares. Over the past year the S&P 500 has risen 4.24% while PYXS has risen 57.55%. PYXS lost -$3.65 per share in the over the last 12 …The Oncology Pharma stock price gained 1999900.00% on the last trading day (Wednesday, 29th Nov 2023), rising from $0.000001 to $0.0200. During the last trading day the stock fluctuated 1900.00% from a day low at $0.0010 to a day high of $0.0200. The price has been going up and down for this period, and there has been a 1900% gain for …Support Resistance, Pivot Points for Pyxis Oncology Inc with Key Turning Points and Technical Indicators. Support Resistance, Pivot Points for Pyxis Oncology Inc with Key Turning Points and Technical Indicators. ... Stocks: 15 20 minute delay (Cboe BZX is real-time), ET. Volume reflects consolidated markets. Futures and Forex: 10 or 15 minute ...On average, Wall Street analysts predict. that Pyxis Oncology's share price could reach $8.67 by Nov 30, 2024. The average Pyxis Oncology stock price prediction forecasts a potential upside of 445.09% from the current PYXS share price of $1.59. As of March 21, 2023, the outstanding number of shares of Common Stock of Pyxis Oncology was 36,980,621. Pam Connealy , Chief Financial Officer of Pyxis Oncology , added, “As our clinical programs have advanced, our team has established a strong financial foundation with no debt and a cash runway into the first half of 2025.PYXS Stock 12 Months Forecast. Based on 4 Wall Street analysts offering 12 month price targets for Pyxis Oncology in the last 3 months. The average price target is $11.67 with a high forecast of $15.00 and a low forecast of $7.00. The average price target represents a 618.15% change from the last price of $1.63.News releases. Year. 2023. Nov 28, 2023. Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer. Nov 07, 2023. Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update. Sep 27, 2023.Significantly high institutional ownership implies Pyxis Oncology's stock price is sensitive to their trading actions. A total of 5 investors have a majority stake in the company with 52% ownership.Pyxis Oncology issued approximately 4.3 million shares of common stock as a result of this transaction, and immediately post-acquisition, Pyxis Oncology is expected to have 43,872,248 shares of ...Asset Growth. -27.76%. Trailing 12-Months. The Pyxis Oncology stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and ...

Cash runway extended to early 2026 due to cost reductions and portfolio prioritization, allows for preliminary data readouts from PYX-201 and PYX-106. Find the latest Pyxis Oncology, Inc. (PYXS) stock quote, history, news and other vital information to help you with your stock trading and investing.A high-level overview of Pyxis Oncology, Inc. (PYXS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Pyxis Oncology expects to issue 4 million of PYXS stock to fuel its purchase of Apexigen. When the deal closes, it will result in current APGN shareholders owning 10% of the combined company.Pyxis Oncology Inc (PYXS) stock is higher by 8.35% while the S&P 500 has fallen -0.1% as of 11:49 AM on Monday, Apr 3. PYXS is higher by $0.33 from the previous closing price of $4.01 on volume of 6,295,868 shares. Over the past year the S&P 500 is down -10.42% while PYXS is higher by 21.17%. PYXS lost -$3.65 per share the over the last 12 months.Instagram:https://instagram. oncology institutegroom insurancetradestation interactive brokersnerdwallet stock price Pyxis Oncology, Inc. (PYXS) Share Price Forecast v/s Share Price Today Below is a chart showing the percentage difference between Pyxis Oncology, Inc.'s share price and its median forecast price. As on 27.11.23, the difference is -75.29% house insurance naples flbest variable life insurance As of March 21, 2023, the outstanding number of shares of Common Stock of Pyxis Oncology was 36,980,621. Pam Connealy , Chief Financial Officer of Pyxis Oncology , added, “As our clinical programs have advanced, our team has established a strong financial foundation with no debt and a cash runway into the first half of 2025. ten year treasury marketwatch Find the latest analyst research for Pyxis Oncology, Inc. Common Stock (PYXS) at Nasdaq.com.ZIM Integrated Shipping Services (NYSE:ZIM) pays an annual dividend of $9.35 per share and currently has a dividend yield of 134.73%. ZIM has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Read our dividend analysis for ZIM.BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers ...